ArticleScientific reports2026
High glucose enhances N
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Colorectal cancer (CRC) is a leading cause of cancer deaths. Advanced glycation end products (AGEs) formed in hyperglycemia, particularly Nε-(carboxymethyl)lysine (CML), promote tumor progression, although its molecular mechanisms remain unclear. Anoctamin 6 (ANO6), a transmembrane protein involved in tumor proliferation, invasion, metastasis, and cell death. It may serve as a critical link between glucose metabolism and CRC progression. This study examined the effects of high glucose and CML on ANO6 expression in T84 CRC cells, and explored the role of ANO6 in cell proliferation and migration. Our findings demonstrate that high glucose and CML upregulated ANO6 expression (p = 0.002 and p = 0.03, respectively), which in turn reduced necrotic cell death through caspase-1 activation and promoted cell migration. Spheroid assays confirmed that high ANO6 expression produced compact spheroids with increased E-cadherin (p = 0.0001). CML further enhanced spheroid integrity and motility. Low glucose increased E-cadherin expression (p = 0.01) but decreased Smad2/3 activity (p = 0.04), while CML exposure restored Smad2/3 phosphorylation and enhanced migration. Taken together, high glucose and CML promote CRC progression through ANO6 upregulation, enhancing migration while suppressing pyroptosis. These findings identify ANO6 as a mechanistic link between metabolic dysregulation and EMT-driven metastasis, highlighting it as a promising therapeutic target. Targeting ANO6 may offer a novel therapeutic strategy for CRC, particularly in patients with hyperglycemia or diabetes-associated metabolic dysregulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.